Latest:
Dr. Couriel Discusses Treating GVHD With Photopheresis
Dr. Daniel Couriel, from the Unversity of Michigan Comprehensive Cancer Center, Discusses Treating GVHD With Photopheresis
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Daniel Sargent, PhD
Latest:
Daniel Sargent on International Collaboration for Colon Cancer Research
Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.
Daniel Von Hoff, MD
Latest:
Dr. Daniel Von Hoff on Combination Treatments for Late Stage Pancreatic Cancer
Daniel Von Hoff, MD, the Physician-in-Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen) and a special consult with Baylor University College of Medicine, discuses combination treatments for pancreatic cancer.
Danielle Brander, MD
Latest:
Dr Brander on Findings From the TRANSCEND CLL 004 Trial in Relapsed/Refractory CLL/SLL
Danielle M. Brander, MD, discusses the primary analysis of the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Danielle Ternyila
Latest:
Camrelizumab/Apatinib Shows Promising Activity in Second-Line Esophageal Squamous Cell Carcinoma
January 15, 2021 - A novel combination comprised of camrelizumab and apatinib was found to have promising clinical efficacy with an acceptable safety profile when used as a second-line treatment in patients with esophageal squamous cell carcinoma.
Danielle Townsley, MD
Latest:
Dr. Townsley on Screening for GATA2 in At-Risk Patients for MDS, AA, and AML
Danielle Townsley, MD, staff clinician, Cell Biology Section, National Institutes of Health, discusses a study which examined screening for GATA2 in patients who are at risk for myelodysplastic syndromes (MDS), aplastic anemia (AA), and acute myeloid leukemia (AML).
Danny Rischin, MD
Danny Rischin, MD, is a professor and director of Medical Oncology at the Peter MacCallum Cancer Centre
Latest:
Dr Rischin on the Safety of Adjuvant Cemiplimab in High-Risk CSCC
Danny Rischin, MD, discusses safety findings from the phase 3 C-POST trial of adjuvant cemiplimab vs placebo in patients with high-risk CSCC.
Danny Rischin, MD, MBBS, FRACP
Latest:
Dr. Rischin on the FDA Approval of Cemiplimab for CSCC
Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the FDA approval of cemiplimab for the treatment of patients with cutaneous squamous cell carcinoma.
Daphne Dumoulin, MD
Latest:
Dr. Dumoulin on NVALT 12 Data in NSCLC
Daphne Dumoulin, MD, discusses the NVALT 12 study, a trial examining paclitaxel/carboplatin/bevacizumab inducing peripheral effector CD8 T-cell proliferation that could be prone to treatment in checkpoint inhibitors in patients with non–small cell lung cancer.